IL129968A0 - use of cntf receptor activators for the treatment of obesity - Google Patents

use of cntf receptor activators for the treatment of obesity

Info

Publication number
IL129968A0
IL129968A0 IL12996897A IL12996897A IL129968A0 IL 129968 A0 IL129968 A0 IL 129968A0 IL 12996897 A IL12996897 A IL 12996897A IL 12996897 A IL12996897 A IL 12996897A IL 129968 A0 IL129968 A0 IL 129968A0
Authority
IL
Israel
Prior art keywords
obesity
treatment
receptor activators
cntf receptor
cntf
Prior art date
Application number
IL12996897A
Other languages
English (en)
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of IL129968A0 publication Critical patent/IL129968A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL12996897A 1996-11-19 1997-11-18 use of cntf receptor activators for the treatment of obesity IL129968A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
PCT/IT1997/000283 WO1998022128A1 (en) 1996-11-19 1997-11-18 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity

Publications (1)

Publication Number Publication Date
IL129968A0 true IL129968A0 (en) 2000-02-29

Family

ID=11404538

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12996897A IL129968A0 (en) 1996-11-19 1997-11-18 use of cntf receptor activators for the treatment of obesity
IL12996805A IL129968A (en) 1996-11-19 2005-07-26 Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12996805A IL129968A (en) 1996-11-19 2005-07-26 Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity

Country Status (14)

Country Link
US (2) US6565869B1 (de)
EP (1) EP0946189B1 (de)
JP (1) JP4067127B2 (de)
CN (2) CN101703761B (de)
AT (1) ATE228003T1 (de)
AU (1) AU727174B2 (de)
CA (1) CA2271781C (de)
DE (1) DE69717308T2 (de)
DK (1) DK0946189T3 (de)
ES (1) ES2187830T3 (de)
IL (2) IL129968A0 (de)
IT (1) IT1288388B1 (de)
PT (1) PT946189E (de)
WO (1) WO1998022128A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CN1250379A (zh) 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂
IT1291114B1 (it) * 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6680291B1 (en) 1998-02-27 2004-01-20 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
DK1165613T3 (da) 1999-03-29 2008-08-25 Procter & Gamble Melanocortinreceptorligander
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
EP1270011A4 (de) * 2000-02-18 2003-06-11 Sumitomo Pharma Wirkstoffe zur verbesserung von gestörter glukosetoleranz
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
JP2003535831A (ja) * 2000-05-24 2003-12-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 毛様体神経栄養因子の使用
EP1290206A2 (de) * 2000-06-09 2003-03-12 University of Florida Rekombinante aav-vektoren für die gentherapie von fettleibigkeit
CA2439682A1 (en) * 2001-03-02 2002-09-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7279282B2 (en) * 2004-07-09 2007-10-09 Scott Mellis Methods for identifying a candidate for treatment of obesity
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104558148B (zh) * 2013-10-17 2018-11-06 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和用途
EP3186242B1 (de) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase
CN107073077B (zh) * 2014-11-07 2020-12-01 陕西麦科奥特科技有限公司 睫状神经营养因子鼻腔给药系统及其制备方法和应用
CN106632650B (zh) * 2015-10-30 2020-11-13 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和应用
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
WO2018128745A1 (en) * 2017-01-06 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
KR20200100089A (ko) * 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
JP2021531328A (ja) * 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ−α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン−アスパラギン酸プロテアーゼを含む薬剤送達系
WO2019246130A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US20230094423A1 (en) * 2019-12-18 2023-03-30 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
US5426177A (en) 1990-06-01 1995-06-20 Regeneron Pharmaceuticals, Inc. Ciliary neurotrophic factor receptor
CS156891A3 (en) 1990-06-01 1992-04-15 Regeneron Pharma Receptor of a cilary neurotropic factor
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
JPH07500725A (ja) 1991-07-23 1995-01-26 シンテックス−シナージェン　ニューロサイエンス　ジョイント　ベンチャー 組換え毛様体向神経因子およびｃ−末端切断毛様体向神経因子の精製ならびに末梢神経障害の処置方法
US5691313A (en) 1991-07-23 1997-11-25 Amgen Inc. Methods of treating impotency with ciliary neurotrophic factor
US5593857A (en) 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
CA2123234A1 (en) 1991-11-11 1993-05-27 Lanfranco Callegaro Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
US5955290A (en) 1991-12-02 1999-09-21 Regeneron Pharmaceuticals, Inc. Assay systems using the CNTF signal transduction pathway
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
IT1284867B1 (it) * 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Also Published As

Publication number Publication date
ITRM960790A0 (it) 1996-11-19
IL129968A (en) 2005-11-20
CA2271781C (en) 2002-11-12
ITRM960790A1 (it) 1998-05-19
CN102145163B (zh) 2013-09-18
DE69717308T2 (de) 2003-07-10
US20030176346A1 (en) 2003-09-18
WO1998022128A1 (en) 1998-05-28
PT946189E (pt) 2003-02-28
DE69717308D1 (de) 2003-01-02
CN101703761A (zh) 2010-05-12
JP4067127B2 (ja) 2008-03-26
EP0946189B1 (de) 2002-11-20
AU5134498A (en) 1998-06-10
DK0946189T3 (da) 2002-12-16
ES2187830T3 (es) 2003-06-16
CN101703761B (zh) 2013-11-20
ATE228003T1 (de) 2002-12-15
IT1288388B1 (it) 1998-09-22
US6960558B2 (en) 2005-11-01
CA2271781A1 (en) 1998-05-28
CN102145163A (zh) 2011-08-10
US6565869B1 (en) 2003-05-20
AU727174B2 (en) 2000-12-07
JP2000511561A (ja) 2000-09-05
EP0946189A1 (de) 1999-10-06

Similar Documents

Publication Publication Date Title
IL129968A (en) Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
MX9805255A (es) Antagonistas de receptor de vitronectina.
MX9603928A (es) Receptores trk humanos e inhibidores del factor neurotrofico.
ES2168376T3 (es) Anticuerpos que activan un receptor de eritropoyetina.
NL300433I2 (en) Methods and compositions for the treatment of glomerulonephritis.
EP1382597A3 (de) Steroidrezeptor-Modulator Verbindungen und Methoden
EP0785793A4 (de) Allosterische modulatoren des nmda-rezeptors
ZA9711435B (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
HU9700636D0 (en) Novel estrogen receptor
ZA952587B (en) Human tumor necrosis factor receptor
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
IL126062A0 (en) Tetrahydrobetacarboline compounds
AU6485496A (en) Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
ZA913043B (en) Soluble,truncated gamma-interferon receptors
IL117159A0 (en) Immunotherapeutic methods and compositions for screening prognosis and therapy
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
ZA976854B (en) Treatment of psychotic disorders.
GB0010488D0 (en) Glutamate receptor modulators and the treatment of psychiatric disorders
ZA983391B (en) Process of producing iron carbide from granular sponge iron.
MX9802380A (es) Formas cortas de quimiocina beta-8.
ZA969285B (en) NK-1 receptor antagonists for the treatment of cancer.
IT1276508B1 (it) Plantare ortopedico a stimolazione variabile.